Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Publikováno v:
Journal of Clinical Oncology. 41:668-668
668 Background: Immunosuppressive factors such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) limit the efficacy of immunotherapies. We have previously reported that histone deacetylase (HDAC) inhibitors have antitumor eff
Autor:
Jennifer King, Rebecca Hassoun, Sandra K. Althouse, Christopher A. Fausel, Bryan P. Schneider, Theodore F. Logan, Nabil Adra
Publikováno v:
Journal of Clinical Oncology. 41:700-700
700 Background: Genomic alterations in RCC can serve as biomarkers for response to therapy. Wild type VHL has shown inferior response to VEGF inhibitors, while patients (pts) with mutated VHL have improved outcomes with immunotherapy (IO)/tyrosine ki
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
S Dropcho, Naomi B. Haas, Roberto Pili, Hao Liu, Vivek Narayan, Lina M Sego, Theodore F. Logan, Sandra K. Althouse, Nabil Adra, Nur P. Damayanti, Paul Monk
Publikováno v:
Journal of Clinical Oncology. 38:5064-5064
5064 Background: Immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) limit the efficacy of immunotherapies. We have previously reported that the HDAC inhibitor entinostat has synergistic antitumor effect in combi
Autor:
David I. Quinn, Justin Budka, Mark Tann, Heather Burney, Hao Liu, Andrew Greenspan, Roberto Pili, James W. Fletcher, Nabil Adra, Nur P. Damayanti, Sara I Edwards, Noah M. Hahn, Mark A. Green, Theodore F. Logan, Costantine Albany
Publikováno v:
Journal of Clinical Oncology. 37:2572-2572
2572 Background: Immunosuppressive factors such as regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been shown to have immunomodulatory effects.
Autor:
Mizue Krygowski, J. P. Maroto, Charles S. White, Theodore F. Logan, Ignacio Duran, Gary R. Hudes, Mark Shapiro, Anna Berkenblit, Maria Cincotta, Janice P. Dutcher
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose Pneumonitis has occurred in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). In a phase III study of patients with previously untreated, poor-prognosis, advanced renal cell carcinoma (ARCC), the mTOR inhibitor tem
Autor:
Amikar Sehdev, Simon J. Warren, Ross Hayden, Theodore F. Logan, William Arthur Wooden, Mathew Joseph Kuhar, Liang Cheng, Douglas J. Schwartzentruber, Lawrence Aaron Mark
Publikováno v:
Journal of Clinical Oncology. 36:e21599-e21599
e21599Background: Prognostic role of BRAF mutation is not well-studied in malignant cutaneous melanoma. We conducted a large retrospective study using a state-wide database to assess the clinical c...
Autor:
Herbert J. Zeh, Paul Monk, Leonard Joseph Appleman, David M. Friedland, Xiaoyan Liang, Theodore F. Logan, David F. McDermott, Jodi K. Maranchie, Rahul Atul Parikh, Daniel P. Normolle, Michael T. Lotze, Lisa H. Butterfield, Marc S. Ernstoff, Thomas Olencki
Publikováno v:
Journal of Clinical Oncology. 36:4573-4573
4573Background: Aldesleukin (recombinant human interleukin-2, IL-2) has been an FDA-approved treatment for mRCC since 1992 with a 5-10% rate of durable complete response. Hydroxychloroquine (HCQ) i...
Autor:
Jacob A. Eitel, Mark A. Green, James W. Fletcher, Theodore F. Logan, Susan M. Perkins, Gary D. Hutchins, Sandra K. Althouse
Publikováno v:
Journal of Clinical Oncology. 36:e16567-e16567
e16567Background: Assessment of TP using 62Cu-ETS PET/CT has been demonstrated in pts with RCC (Fletcher et al, J Nuc Med 2015; 56:56-62, Logan et al, ASCO 2014; abstr 11110) compared to 15O-water ...